| Previous Close | 32.52 |
| Open | 32.55 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 32.30 - 32.81 |
| 52 Week Range | 27.60 - 56.44 |
| Volume | 5,603,626 |
| Avg. Volume | 7,554,876 |
| Market Cap | 33.13B |
| Beta | 0.52 |
| PE Ratio (TTM) | 418.08 |
| EPS (TTM) | 0.08 |
| Earnings Date | N/A |
| Dividend & Yield | 1.36 (4.38%) |
| Ex-Dividend Date | 2017-06-01 |
| 1y Target Est | 36.83 |
- Forbes•26 minutes ago
Facebook, Baidu, Coach And 5 Other Blue-Chip Stocks To Buy For Second-Half 2017
The bull market that kicked off in March 2009 should be on the front cover of AARP magazine. At age 8, it's very old and very overvalued compared to its historical ratios. Given the less than stellar circumstances, how should you invest now?
- Accesswire•yesterday
Today's Research Reports on Stocks to Watch: Geron Corporation and Teva Pharmaceutical
NEW YORK, NY / ACCESSWIRE / June 23, 2017 / It was a disappointing day for Teva Pharmaceutical Industries on Thursday, but judging by the gains the stock saw yesterday nobody would have known it. The pharmaceutical ...
- Zacks•2 days ago
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
